$INO Know what You Own๐Ÿ’ชStay Strong Stay Bull Strong๐Ÿ’ช๐Ÿ˜‰ INO-4800 100% of trial participants demonstrated overall immune responses 95% had seroconverted by antibody response overall Nearly 90% generated strong T cell responses, including CD8+ T cell responses Reported favorable INO-4800 animal challenge data in mouse and non-human primate (NHP) studies; NHP challenge data at 13 weeks post last immunization showed robust memory immune responses and protection from virus replication in both nasal passages and lower lungs INO-5401 Presented positive 12-month overall survival efficacy data demonstrating 85% survival rate for DNA immunotherapy candidate INO-5401 in treatment of glioblastoma multiforme (GBM) VGX-3100 Reported positive Interim Phase 2 results for DNA immunotherapy candidate VGX-3100 in treating HPV associated anal and vulvar dysplasia; VGX-3100 REVEAL 1 pivotal Phase 3 data for HPV -associated cervical dysplasia on track to be reported in 4Q2020 ir.inovio.com/news-releases...
  • 12